JP Morgan saw key M&A activity, new approaches from key UK pharma, a buzz about cell and gene therapy and concerns about the ongoing impact of the US Government shutdown. I’ve written a short blog on my perspective here.
On Brexit, the vote tomorrow is a key watershed, but for our sector we expect ongoing detail from the government on no-deal contingencies. We will focus our analytical and briefing capability on providing members with actionable information, in what is a very uncertain political context.
Key M&As set a positive tone for JPM 2019, as the sector shrugged off US stock market setbacks at the end of 2018. First out of the blocks were GSK taking Tesaro in a £3.8bn deal (announced before the conference) and since ringing in the new year we’ve seen Takeda complete their acquisition of Shire, Bristol-Myers Squibb acquire Celgene in a record breaking £70bn deal and Eli Lilly purchase Loxo Oncology for £6.24bn. These large pharma deals show desire for a strategic pipeline and prove the inherent value of biotech as a driver of innovation. More than half of new drugs registered in the coming years are expected to be made by small companies which large players may then look to add to their portfolio. The outlook for M&As looks strong and venture are keen to put money to work knowing the
Arecor Limited is pleased to announce its participation at PEPTalk 2019’s Protein Science Week. This leading international conference and one of the largest annual gatherings of over 1,300 protein science researchers in the world, will be held between January 14-18, 2019, at the Hilton Hotel, San Diego Bayfront, San Diego, California, USA.
On 14 November 2018, the Supreme Court handed down its judgment in the case of Warner Lambert v Generics. One of the key issues in the case was the scope of the test of “plausibility” which relates to the information a patent must contain.
The BIA intervened in this case requesting that a balance be struck that neither unfairly penalises bioscience companies in requiring an unwarranted level of information in order to demonstrate plausibility of an invention (e.g. clinical trial data) nor permits applicants to unfairly close down areas of research through the filing of speculative patent applications providing only vague indications of possible research objectives.
What is the #FutureofImmunology in the UK? Watch to see Ailsa Bosworth MBE (Founder and CEO of the National Rheumatoid Arthritis Society), Peter Openshaw (President of the British Society for Immunology) and Lisa Olsen (Vice President, R&D, Head of Abbvie Bioresearch Centre) explain why the future is bright #AdvancingTogether
Process intensification, biotechnology, electrification, artificial intelligence, additive manufacturing and advanced materials are changing the face of manufacturing. Deciding which technologies to adopt at what point in the development cycle is critical to business survival and growth. Rapid Techno-Economic Analysis (TEA) modelling informs timely decision making and business strategy. Increasingly companies need in-house capabilities to adapt effectively to the opportunities and risks of new manufacturing technologies, yet these skills are not always readily available.
LifeArc, a leading UK medical research charity, is delighted to launch a new Technology Transfer Fellowship programme in partnership with Imperial Innovations, Queen Mary Innovation and UCL Business (UCLB), the technology transfer offices for Imperial College London, Queen Mary University London and University College London, respectively. The new initiative will provide successful Fellowship applicants with training and experience in four of London’s leading technology transfer environments.
Discovery Park - and some of the businesses driving its success - will use one of the UK’s leading science events to showcase why it remains the perfect location for science companies looking to grow and collaborate. It will be attending Genesis 2018 with several of its life sciences tenants, showcasing their activities and discussing its plans for the future development of the Park.